Cancer Trials Australia's CEO, Dr Kurt Lackovic, was recently invited to speak at an international webinar showcasing Melbourne as a premier location for the conduct of Phase 1 clinical trials. Aimed primarily at international [...]
More patients will have access to potentially life-saving cancer therapies as a result of Epworth joining forces with Cancer Trials Australia. With the addition of Epworth, CTA now has [...]
I am pleased to share the Cancer Trials Australia 2016 Annual Report. Download the 2016 Annual Report Here. 2016 saw growth in CTA membership and corresponding CTA service activity. CTA welcomed [...]
Cancer Trials Australia (CTA) is pleased to announce that Linear Clinical Research has signed a Members Agreement to join the CTA Member Network The CTA network now includes 24 [...]
Cancer Trials Australia (CTA) is proud to be part of the successful Cancer Council Victoria (CCV) grant application for the establishment of a cancer clinical trials network across seven [...]
Chairman of the Board, Professor Andrew Scott, with great pleasure advised that the next Chief Executive Officer of Cancer Trials Australia (CTA) will be Dr Kurt Lackovic. Professor Scott said [...]
Cancer Trials Australia (CTA) announced today that the Shepparton Hospital, through Goulburn Valley Health, and Northern Adelaide Cancer Centre Clinical Trials Unit, operating as the Lyell McEwin Hospital, have [...]
A new RAF-targeted therapeutic has shown early promise against tumours in Phase 1 trials. Doctors Jayesh Desai (1), Ben Solomon (2) and Hui Gan (3)have established a highly successful collaboration [...]
Cancer Trials Australia (CTA) announced today that South West Healthcare had signed an agreement to join CTA. "Southwest Healthcare located at Warrnambool in Victoria services a large population over South [...]
The Board of Directors of Cancer Trials Australia (CTA) today announced the appointment of Professor Andrew Scott as Chairperson.This appointment was made by the Board following the resignation of Professor [...]
